105 :105.06.27 :2 :
1 2 92 3 4
82 85 88 91 95 98 102 5.97 10.70 5 6 6 921031 11 1031114 7,848.94 2,374.30 7 7 8 90 109
971 48 9 9 10 369 431 1539 547 18.95% 10 102 2 4 53 29 10 44 20 24 77 10 20 (1056) 1,414 System () 11 12
() () () () 13 96.12 99.01 100.01 101.01 102.01 103.01 14 15 15 1.1.1 16
+ 17 18 BSC 19 20
21 22 40 40 3 7 - - 23 24
25 % % () 101 102 103 104 65(%) 65(%) (%) (%) 26 65 36.46% 6.63% 105104 5.56% 1,200,000 1,000,000 800,000 600,000 400,000 200,000 0 1,066,529 1,079,570 1,114,422 372,591 27 28
105104 17.57% 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 80,989 85,619 87,734 34,114 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 1 2 3 4 5 6 7 8 9 10 11 12 103 76.1%78.0%84.3%83.5%83.8%85.0%86.6%84.7%83.2%84.3%82.6%81.1% 104 82.2%70.9%84.6%83.6%85.0%86.6%86.0%83.3%82.8%82.9%86.7%85.6% 105 82.4%75.3%87.6%86.3% 105104 2.6% 29 30 105104 8.97% 31 32
105 106 8 8 0 1 1 0 4 0 4 2 0 2 3 0 3 33 1 0 1 19 9 10 33 34 / / / / / 35 36
38 12 37 37 38 38 39 39 39 40 101
41 42 43 101 44
45 45 ) 103 (104-107) 46!! 47 48
49 50 104 51 SNQ SNQ SNQ 52
53 54 55 56
SCI SCI 104 142 64,956 53 114,934 % 105 16 66,819 21,966 % 101-105 64.8%34.9% 57 58 () 100~10412IRB107103 281041-124050 98 1033+1 59 59 60
61 () 62 62 63 64
65 66
2016/6/13 1 2016/6/13 2 2016/6/13 3 2016/6/13 4
2016/6/13 5 2016/6/13 6 2016/6/13 7 2016/6/13 8
(1/4) (2/4) 2016/6/13 9 2016/6/13 10 (3/4) (4/4) 2016/6/13 11 2016/6/13 12
(1/2) (2/2) 2016/6/13 13 2016/6/13 14 (1/2) (2/2) 2016/6/13 15 2016/6/13 16
2016/6/13 17 2016/6/13 18 () 2016/6/13 19 (1/2) 2016/6/13 20
(2/2) () 2016/6/13 21 2016/6/13 22 2016/6/13 23 2016/6/13 24
(1/2) 2016/6/13 25 2016/6/13 26 (2/2) (1/2) 2016/6/13 27 2016/6/13 28
(2/2) 2016/6/13 29 2016/6/13 30 2016/6/13 31
1 0 5
- -
- ( )
(1/2) (2/2) 1 2 3 4 5 6 17 10,000 30,000 30,00050,000 50,000
19
10067 ()
()
10347 23 3 25 2
( ) () ( ) ()
240800-286-586 07-3468008 1000
105627
Health care-associated infections Infections acquired while in the health care setting, with a lack of evidence that the infection was present or incubating at the time of entry into the health care setting Horan TC, et al. Am. J. Infect. Control 36:309
Infectious Agent Transmission / Small particle aerosols (droplet nuclei5μ) Large particles (Droplets 5μ): Susceptible Host http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/isolation2007.pdf 2016/6/13 (airborne precautions) (droplet precautions) (contact precautions) (standard precautions)
(airborne precaution) 6-12 (HEPA filter) () (N95) 3~960 15 90 (droplet precaution) : ( 3 ) (cohorting care) () ~
() (MRSA,VRE,CRAB,CRE) :, (cohorting care) () non-critical device( )
Sarcopte s scabiei Scabies) : 1.:Benzyl benzoate lotionbb LotionEurax cream3~7 ** 2.(50)10 3. 4.: X 為 VRE 培 養 陽 性 部 位 The Risk of Hand and Glove Contamination after Contact with a VRE (+) Patient Environment. Hayden M, ICAAC, 2001, Chicago, IL.
(PPE) (,,) / PPE,PPE,/ / /, / Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007
? 150 103~104 Lancet Infect Dis 2006;6:641-52 32
:
/ : :
1. 2./ 3. 4. 5. () 0.5 40-60 20-30
() CNS14774 1. 2. 3., 4. 5.,, 6. : (- -N95) /
N95 (1)() (2) : : : : : : : : 1.: () 2./: 3. : : N95 4.: 4 N951 2016/6/13
N95 N95 1. 2. 3. 7. 8. 9. 4. 2016/6/13 5. 6. 10 2016/6/13 vs PPE Use in Healthcare Settings
CDC, Taiwan
1.>38()( ) 2. 3.(2)
1 () 2 E-MAIL icn@vghks.gov.tw) 66-1
-2-3 TOCC- / 38 2016/6/13 71
CDC, Taiwan
8 78 (,,..) 0.9%NS Infection control (PPE) () ( ) 1.HBV HCVHIV VDRL 2. 3. Proactive/systemic versus reactive/individual approach Professor Didier Pittet, Geneva
-
(Zika 110 4IgM 3 12 11 3~ 12 it b L i P d 2~ 7 0 5 10 5. 75% (New Engl J Med Feb 10, 2016 Online First) 80 ()
TOCC 219 316-17 14 ry --------------------------------------------------- Kaohsiung Veterans General Hospital Tel07-342-2121 ext.34343468298 Fax07-346-8292 Emailju0516@vghks.gov.tw ---------------------------------------------------
Plan 1 Plan 2 Plan 3 - Plan 4 Plan 5 MDR(DOTS-Plus) Plan 6 Plan 7 Plan 8 Plan 9 Plan 10 Plan 11 Plan 12 Plan 13 Plan 14 & (PETTSDOTS ) Plan 15 : 1. 2. 3.
DOTS() (Direct Observed Treatment, Short Course) DOTS () -- : 都 治 關 懷 員 隨 同 公 衛 護 士 至 醫 院 訪 視 病 人 教 導 病 人 認 識 結 核 病 及 都 治 計 畫 的 簡 介 關 懷 員 送 藥 到 約 定 地 點 個 案 到 點 服 藥 關 懷 員 家 訪 送 藥
:
- 1.Isoniazid (INH) 9(270) 2.3HP-Isoniazid (INH) + Rifapentine (RPT) 123 <13 96% MDR INHRMP
(1.2.3.4)
(20133) 34 36
(LIS) (LIS) Source -+ Contact - Environment - / X / 10 > > < > < >
() () HEPA filter
()
) PCR
X X X X
100&1 & & & & &
:/ /
??
(a)(sender) (b)(transmission) (c)(receiver) (d)(feedback)
1. - - 2. - - - -
000() 000()
A 3 B A B C D E F
.............. 1 2 3 4 5
1 2 3 4 37 1. 2. 3. 4. 5. 6. 1. 2. 3. 4. 1. 2. 3. 4.
1. 2. 1. / 2. ( ).. 1...(.) 2. 41 42 1. 2.. 3. 4. 43
-1-2
Nr.
w72-21 w65-11
.............